Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Illumina

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Sep 21, 2020

Illumina to Acquire Grail for $8B in Cash and Stock

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

Jul 20, 2020

Canexia Health Sees Canadian Liquid Biopsy Initiative as Springboard to Wider Adoption

Premium

The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.

May 27, 2020

Illumina, Genomic Medicine Sweden to Evaluate Sequencing-Based Leukemia Diagnostics

The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.

Apr 10, 2018

Illumina, Loxo Oncology to Develop Pan-Cancer Companion Diagnostic

The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.

What's Popular?

In Illumina

  1. Illumina to Acquire Grail for $8B in Cash and Stock

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.